Alere Logo Continuing Medical Education 
Learning at your convenience. On your schedule.
Arch 
  Alere offers a number of educational webinars throughout the year on a wide range of practical topics directed toward healthcare professionals. You can register for upcoming sessions here, or watch archived webinar recordings at any time, from anywhere. These Alere events are delivered by respected leaders in the world of healthcare, and managed by Whitehat Communications to ensure a professional environment.

All programs are free, and in most instances offer PACE® Continuing Education Credits for up to six months after the live event. Check back often for new event postings. 
Healthcare Transformation: Collapsing Silos to Optimize Outcomes
Wednesday, October 1, 2014 | 1:00 - 2:00 PM Eastern
PACE® credit available until April 1, 2015  |  Florida Laboratory CE Credit available for live event
Register
In 2013, CMS began implementing Value Based Purchasing (VBP), a strategy that shifts from pure volume-based payment, like fee-for-service payments, to payments that tie patient outcomes to reimbursements. VBP's three key elements - quality, cost and patient satisfaction determine whether or not a hospital will receive full or partial reimbursement. These elements are all dependent on a shared cooperative effort among departments within the hospital.
Unfortunately, this inter-departmental cooperation has proven to be elusive for most hospitals. As a result, the transition to VBP has been a rocky one for hospitals across the US, as reflected by reduced reimbursements and vanishing profits.

This webinar will illustrate how hospitals that encourage departments to communicate and cooperate are more likely to improve patient outcomes and avoid reimbursement penalties, while conversely, those with fragmented departmental "silos" that function independently of one another, struggle with the transition.

The session will also review CMS' Healthcare Transformation Targets and Measures, analyze why shared responsibilities and goals impacts outcomes, and demonstrate how a collaborative care model closes the gaps in delivery of care.


This webinar will:
• Review CMS Healthcare Transformation Targets and Measures
• Analyze why the shared responsibilities and goals impacts outcomes
• Demonstrate how a collaborative care model closes the gaps in delivery of care



Click here to learn more about Alere's diagnostics solutions to optimize outcomes
Presenter:
Sandra Sieck, CEO
Sieck HealthCare, LLC
Sandra Sieck photo
Sandra Sieck leads a nationally known consulting company that specialized in healthcare operations and management. Having worked with over 2000 hospitals in the U.S., she has been published in national and international publications. She has advised and presented to hospitals and organizations such as CMS, National Quality Forum, National Institute of Health, American College of Cardiology, the American College of Healthcare Executives, and the American College of Emergency Medicine.
   
Diagnostic Testing for C. difficile and Nosocomial Diarrhea: Where are we Now?
Due to the anticipated popularity of this webinar, it will be presented twice:
Tuesday, September 23, 2014 | 11:00 AM EST and Thursday, September 25, 2014 | 4:00 PM EST
PACE® credit available until March 25, 2015  |  Florida Laboratory CE Credit available for live event
Register for Sept. 23rd Session

Register for Sept. 25th Session
Clostridium difficile has emerged as one of the most important causes of nosocomial diarrhea and healthcare-associated infection but positive test results do not necessarily correlate with clinical disease. Exclusive reliance on bacterial antigen or DNA-based tests for C. difficile diagnosis results in overdiagnosis, overtreatment, and elevation of institutional rates of C. difficile infection with an unknown effect on individual patient outcomes.

This webinar will summarize the strengths and limitations of common C. difficile test methods and discuss the potential role of adjunctive tests such as fecal lactoferrin in distinguishing colonization from infection and assessing disease severity. The session will also review the role of inflammation in C. difficile infection and criteria for mild-moderate vs. severe disease. Other common causes of nosocomial diarrhea besides C. difficile will also be briefly covered.

This webinar will:
• Analyze the strengths and limitations of tests for C. difficile DNA or antigens vs. toxins
• Review the role of inflammation in C. difficile infection and criteria for mild-moderate vs. severe disease
• Discuss 5 common causes of non-C. difficile diarrhea in hospitalized patients

Click here to learn more about Alere's Antimicrobial Stewardship solutions.


TTT graphic






This webinar is sponsored by Alere and Cardinal Health      Alere/Cardinal logo jpg
Presenter:
Christopher Polage, MD
Asst Prof. of Pathology and Infectious Diseases
University of California, Davis
Chris Polage photo
Dr. Christopher Polage is an Assistant Professor of Pathology and Infectious Diseases at the University of California, Davis and the Director of the Clinical Microbiology Laboratory at the UC Davis Medical Center in Sacramento, California. His research focuses on understanding the role and significance of laboratory testing in hospitalized patients with diarrhea, and suspected C. difficile infection, in particular. He has conducted outcome studies to investigate the relationship between test results and clinical outcomes in patients tested for C. difficile infection and authored several publications regarding the evaluation and treatment of patients with nosocomial diarrhea and the performance of C. difficile diagnostic testing.
   
Community-Acquired Pneumonia: A Case for Test, Target, Treat
Live Event: Tuesday, February 18, 2014 1:00 - 2:00 PM EST
PACE® credit available until August 17, 2014  |  Florida Laboratory CE Credit available for live event
This program has been approved by the American Association of Critical-Care Nurses (AACN) for 1.0 CERP, Synergy CERP Category A, File Number 00018662
View RecordingView Slides
For patients with Community-Acquired Pneumonia (CAP), the current standard of practice is to start therapy using broad-spectrum antibiotics with the goal to cover the most likely pathogens. Since the initial standard microbiological work-up fails to identify a definitive pathogen in the majority of patients, most patients are continued on broad-spectrum antibiotics for the full duration of therapy. This current antimicrobial approach exposes patients to more antimicrobials than necessary. It eradicates a significant proportion of protective organisms belonging to the normal host flora and opens the door to antimicrobial resistant pathogens.

Advances in diagnostic testing have allowed us to identify respiratory pathogens of CAP earlier. These advances have increased the potential for identifying specific pathogens in a greater proportion of patients, allowing improved directed therapy that targets the identified pathogens. Using this directed therapy, antibiotics can be reduced or “de-escalated.” A new paradigm of “targeted antimicrobial” treatment will reduce antimicrobial resistance, lower costs and limit adverse events. This webinar will review the pathogens responsible and the diagnostic and treatment options available for CAP, and demonstrate how a stewardship committee can develop CAP guidelines to better direct therapy leading to improved patient care.

This webinar will:
• Review the pathogens responsible for community-acquired pneumonia
• Analyze the diagnostic and treatment options available for CAP
• Demonstrate how a stewardship committee can develop CAP guidelines to better direct therapy leading to improved patient care



Click here to learn more about Alere's Antimicrobial Stewardship solutions.



TTT graphic
Presenter:
Thomas M File, Jr. MD MSc. MACP FIDSA FCCP
Chair, Infectious Disease Division
Summa Health System, Akron, Ohio
Thomas File Photo
Dr. File is Chair of the Infectious Disease Division at Summa Health System in Akron, Ohio, USA and Professor of Internal Medicine, Master Teacher, and Chair of the Infectious Disease Section at Northeast Ohio Medical University in Rootstown, Ohio. Dr. File is a Master of the American College of Physicians, a fellow and a past member of the Board of Directors of the Infectious Diseases Society of America (IDSA), and a fellow of the American College of Chest Physicians. He is President of the Board of Directors of the National Foundation for Infectious Diseases.
   
Antibiotics: Managing a Medical Treasure
Live Event: Friday, January 31, 2014  1:00 PM EST
PACE® credit available until July 30, 2014  |  Florida Laboratory CE Credit available for live event
View RecordingView Slides
Antimicrobial agents are a remarkable class of drugs that are responsible for some of the most dramatic improvements in medical therapy in history. However, these medicines are also the only class of drugs whose efficacy diminishes as we use them. The link between antibiotic use and the development of resistance has been repeatedly made since the 1950s, yet clinicians have not learned from mistakes that have occurred with the introduction of new antibiotics. The development of resistance to carbapenems is now one of the greatest challenges to medicine since there is little on the horizon for patients suffering from carbapenem-resistant, gram-negative infections. Clinicians must realize how perilously close we are to a ’post-antibiotic’ era.

While no one doubts the importance of infection control practices in limiting the spread of antibiotic-resistant organisms, optimizing antibiotic use, also known as antibiotic stewardship, remains essential for successful control of the antibiotic resistance. Approaches to optimize antibiotic use vary in their effectiveness; some interventions are restrictive while others are persuasive. The overriding premise that antimicrobials are medical treasures, should guide all prescribers whenever these drugs are used. Once begun, their continued use must be scrutinized. Antibiotic de-escalation is a complex concept comprised of three questions: Is the patient actually infected at all? Is the patient actually infected with bacteria? How long do you need to treat with antimicrobials?

This webinar will:
• Analyze the relationship between antibiotic use and antibiotic resistance
• Review the reasons for the dearth of new antibacterial antibiotics
• Discuss the need for antibiotic stewardship
• Describe the methods for optimizing antibiotic use including the use of biomarkers, newer diagnostic tools and approaches to deescalate antibiotics


Click here to learn more about Alere's Antimicrobial Stewardship solutions.


TTT graphic
Presenter: 
Robert Gaynes, MD
Professor of Medicine
Emory University School of Medicine
Robert Gaines photo
Dr. Gaynes is Chair of the Antimicrobial Stewardship Committee and Infection Control Committee at Emory University School of Medicine and the Atlanta VA Hospital. Dr. Gaynes has authored and/or coauthored over 145 papers/book chapters on infectious disease topics and in 2011 published a book entitled, Germ Theory: Medical Pioneers in Infectious Diseases.
APUA Logo
   
The Clinical Impact of Antimicrobial Stewardship and Rapid Diagnostic Tests:
From Bench to Bedside

Live Event: Thursday, December 12, 2013 1:00 PM EST
PACE® credit available until June 11, 2014  |  Florida Laboratory CE Credit available for live event
View RecordingView Slides

With the current global crisis in antimicrobial resistance and the threat of a return to the preantibiotic era, it is increasingly urgent that physicians recognize the need for, and the value of antimicrobial stewardship programs (ASPs) and support their existence. ASPs can help avoid inappropriate antimicrobial use and help preserve the efficacy of these important resources.

The clinical microbiology laboratory plays a critical role in antimicrobial stewardship by providing patient-specific culture and susceptibility data to optimize individual antimicrobial management and by assisting infection control efforts in the surveillance of resistant organisms. Early initiation of effective antimicrobial therapy is associated with improved patient outcomes, and rapid pathogen identification and notification to the treating clinician is a key component. Combining rapid diagnostics with antimicrobial stewardship interventions could facilitate the selection dosing and duration of empiric appropriate antimicrobial therapy, avoiding the prolonged unnecessary use of antimicrobial agents while awaiting culture results.

This presentation will outline current trends in resistance and will analyze the value of ASPs in acute care hospitals. It will examine the role of rapid diagnostics in a successful stewardship program, with a particular emphasis on managing and controlling C. difficile, the most common cause of healthcare-associated infectious diarrhea. The session will also analyze various practical methods in which rapid diagnostics information can be brought from the bench to the bedside.

This webinar will:
• Review trends in antimicrobial resistance and C. difficile infections
• Discuss strategies for implementing antimicrobial stewardship in acute care hospitals
• Analyze various ways in which rapid diagnostics information can be brought from bench to bedside

 

 

Click here to learn more about Alere's Antimicrobial Stewardship solutions.

TTT graphic

Presenter:
Lilian Abbo, MD
Associate Professor of Clinical Medicine
Division of Infectious Diseases, University of Miami
Miller School of Medicine
Lilian Abbo Picture
Dr. Abbo's clinical and research areas of interest are in antimicrobial stewardship and transplant associated infections. Dr. Abbo has been an active member of the Infectious Diseases Society of America Standard and Practice Guidelines Committee and a committee member of the International Society of Chemotherapy, Antimicrobial Stewardship Working Group. She has published numerous original research and review articles in antimicrobial stewardship and immunocompromised host-associated infections.
APUA Logo
Measuring the Impact of Antimicrobial Stewardship in Healthcare Settings
Live Event: Tuesday, July 2, 2013 1:00 PM EDT
PACE® credit available until January 1, 2014  |  Florida Laboratory CE Credit available for live event
This program has been approved by the American Association of Critical-Care Nurses (AACN) for 1.0 CERPs, Synergy CERP Category A, File Number 00018442
View RecordingView Slides 
While the widely appreciated benefits of antibiotic therapy have revolutionized healthcare over the past fifty years, we are now experiencing worldwide escalating resistance to these irreplaceable drugs. More than $1.1 billion is spent annually on unnecessary antibiotic prescriptions for respiratory infections in adults. In total, antibiotic resistance is responsible for $20 billion in excess healthcare costs, $35 billion in societal costs, and 8 million additional hospital days. Optimizing their use, particularly in hospitals, has become a critical imperative that we all must embrace. Antimicrobial stewardship programs (ASPs) have evolved as the primary intervention to address this issue.

This presentation will discuss the basic and most easily implemented programmatic features of ASPs to help guide participants in implementing the key elements of such a program. Related topics will include a discussion of the role of new diagnostic tools that allow for more informed and targeted use of antibiotics.

This webinar will also analyze various approaches to the measurement of both antibacterial use and the success of a hospital's ASP. Discussion will include the origins, scope, and threat of antibacterial resistant microbes, the four basic elements of successful antimicrobial stewardship, and the ways in which rapid diagnostics play a key role in successful antimicrobial stewardship.

This webinar will:
Discuss the origins, scope, and risks of antibacterial resistance
• Review the trends in the approval and introduction of new antibacterial agents over the past 30 years
• Summarize the four basic elements of successful antimicrobial stewardship
• Analyze various approaches to the measurement of both antibacterial use and the success of a hospital's ASP
• Examine the ways in which rapid diagnostics play a key role in successful antimicrobial stewardship

Click here to learn more about Alere's Antimicrobial Stewardship solutions.

Presesnter:
Philip Carling, MD
Professor of Clinical Medicine
Boston University School of Medicine

Dr. Philip Carling

This webinar is produced by the Alliance for the Prudent Use of Antibiotics and is funded by an unrestricted grant from Alere.©2013 Alliance for the Prudent Use of Antibiotics (APUA) licensed to Alere Inc TTT campaign.
APUA logo
Finding Pneumo 2: In Search of Legionella
Live event: Thursday, April 25, 2013 1:00 PM ET (10:00 AM PT)
PACE® credit available until October 25, 2013  |  Florida Laboratory CE Credit available for live event
View RecordingView Slides
The incidence of Legionnaires' disease is rising throughout the world. The number of cases of Legionnaires’ disease reported to CDC has doubled from 2000 to 2009. Climatic changes and more frequent use of diagnostic tests are the likely reasons for the increase. Legionella is the second most common type of pneumonia within an ICU and is as common in a patient with an ambulatory pneumonia presenting to the ED as it is to a patient admitted to the hospital with a severe pneumonia. Mortality is high if appropriate antibiotic therapy is not given early.

Misconceptions about Legionnaires' disease abound. We will evaluate the controversies surrounding Legionnaires disease, including:
• Is aspiration as a mode of transmission more frequent than aerosolisation?
• Are cooling towers over-rated as a source of the disease?
• What role does hospital tap water play in spreading Legionnaires’ disease?

Traditional outbreaks affect large numbers of people in a short period of time, whereas in the case of Legionnaires’ disease, sporadic cases of are much more common. This webinar will evaluate the methods that will provide a more accurate diagnosis of Legionella, and will assist you in identifying the source and nature of the outbreak.

Finding Pneumo cropped graphicThis webinar will:
• Identify the source of Legionella and its mode of transmission
• Analyze the laboratory methods used for diagnosis of Legionnaires' disease
• Describe the optimal treatment and role of empiric therapy for Legionnaires' disease
• Discuss the role of culture on selective media and urinary antigen testing



Click here to learn more about Alere's Legionella testing solutions.

Presenter:
Victor L. Yu, MD
Professor of Medicine
University of Pittsburgh

Victor Yu Photo
C. difficile Testing in the PCR Era: The Role of Clinical Outcomes
and Laboratory Diagnosis
Live event: Tuesday, March 26, 2013 11:00 AM ET (8:00 AM PT) and 2:00 PM ET (11:00 AM PT)
PACE® credit available until December 20, 2015
View RecordingView Slides
Due to the anticipated high demand for this webinar, it will be presented live twice on March 26th.

Despite years of study, there remains a lack of consensus on laboratory diagnostic strategies for managing Clostridium difficile infection. Clinical outcomes are often overlooked when considering the available laboratory methods, which limits the interpretation of results.

This one-hour webinar will delve into the recent landmark study on behalf of the U.K. Department of Health that compared clinical indicators of disease with current laboratory methods including gold standards, EIA and PCR on over 12,500 clinical samples across the country. The results of this study have advanced the understanding of C. difficile disease diagnosis and are the cornerstone of the U.K. DoH guidelines published in 2012.

This webinar will:
• Discuss the findings from the most comprehensive study conducted to date on C. difficile diagnostics
• Explore the clinical context of infection diagnosis
• Describe the clinical impact of C. difficile testing methods and algorithms

Click here to learn more about Alere's C. difficile solutions.
Presenter:
Mark Wilcox, B Med Sci, BM, BS, MD, FRCPath
Professor of Medical Microbiology
University of Leeds, Leeds, UK

Mark Wilcox Photo
   
Containing Healthcare Associated Infections Through Antibiotic Stewardship
Live event: Wednesday, November 14, 2012  1:00 PM EST
PACE® credit available until May 13, 2013  |  Florida Laboratory CE Credit available for live event
View RecordingView Slides 
A recent study found that antibiotic-resistant infections can add nearly 13 hospital days per patient, and up to $26 billion in annual US healthcare costs*. The number of hospitalizations associated with C. difficile infections has tripled to 335,000 annually, while the number of deaths has quadrupled in the past decade.

New ESBLs have evolved dramatically in the recent decades, such that few treatment options remain for infections caused by these exceptionally resistant pathogens. And of the estimated 478,000 US hospitalizations with S. aureus infection, approximately 58% were related to MRSA. Antimicrobial Stewardship Programs (ASPs) are recommended by the CDC and IDSA as essential in controlling these most problematic infections. This webinar will describe the nature of antimicrobial resistance, identify trends of major resistant infections, and delineate the important components of successful antimicrobial stewardship.

This webinar will:
• Describe trends of major HAIs including MRSA, ESBLs and C. difficile
• Review the causes and mechanisms driving antibiotic resistance problems
• Explain the link between antibiotic overuse and the emergence of resistant infections
• Review effective ASP practices and the importance of diagnostics in improving antibiotic treatment and minimizing resistance
• Illustrate specific examples to enhance hospital-based antimicrobial stewardship

*Study Sponsored by Alliance for the Prudent Use of Antibiotics, conducted at Cook County Hospital (CID Oct 2009)
Presenters:

Stuart Levy, M.D.
Professor of Medicine

Tufts University School of Medicine
President, APUA
Stuart Levy Photo

Shira Doron, M.D., M.S.
Assistant Professor of Medicine
Tufts University School of Medicine
Shira Doron Photo
   
The Past, Present and Future of Blood Gas and Electrolyte Testing
Live event: Wednesday, November 7,  2012  11:00 AM EST
· PACE® credit available until May 6, 2013
· Florida Laboratory CE Credit available for live event
· Application has been made to the American Association for Respiratory Care (AARC) for continuing education contact hours for respiratory therapists.
View RecordingView Slides
Blood gas and electrolyte sensor technology has existed for close to a century. Over time, the base technology has remained remarkably unchanged but has become miniaturized to allow practical and routine analysis of blood gases and electrolytes for virtually all patients. The original sensors were large and therefore only useful for analyzing large sample volumes. Today’s sensors are just millimeters in diameter, and can measure samples as small as 100 microliters.

This presentation will take an historical journey from the past to the present and into the future of blood gas and electrolytes testing at the point of care. It will review the clinical applications of blood gas and electrolyte measurement in patient care and trace the evolution of this technology from its origins to today’s modern miniature sensors. It will also demonstrate how technologies have and will continue to evolve, allowing a deeper patient care experience by uniting the patient, provider and technology.

This webinar will:
· Review the applications of blood gas and electrolytes testing in patient care
· Trace the evolution of blood gas and electrolytes technology from its origins to today’s miniature devices
· Describe how the unique characteristics of various systems and their potential impact on patient care and robust process improvement

Click here to learn more about Alere's blood gas and electrolyte solutions
Presenter:
Thomas I. Koshy, Ph.D.
Senior Director, Scientific Affairs
Alere
Tom Koshy photo
   
The ABCs of ACOs
Live event: Monday, November 5, 2012  1:00 PM EST
PACE® credit available until May 4, 2013  |  Florida Laboratory CE Credit available for live event
 View RecordingView Slides
There is ample documentation that many areas of our health care system are inefficient and unsustainable. Our current system of health care delivery, spiraling costs, misaligned incentives, defensive medicine, and multiple other factors have created a questionable future for health care that affects us all. As a nation, we are not getting the healthcare we need because the system promotes disease treatment over disease prevention. Reform to our health care system is needed and inevitable, regardless of election results and promised (or threatened) legislation. One feature of this reform appears to be the Accountable Care Organization (ACO).

Unlike our current healthcare structures, which address individual events of compromised health, an ACO can be described as a healthcare structure managing the health of the individual through his or her lifetime. By extension, the ACO may become the structure to manage the health of population segments, not just individuals. This presentation will describe some of the proposed ACO models, analyze some data reflecting the current state of our American health care system, and present data on existing ACO models to illustrate some successes they have already achieved. 

This webinar will:
• Review some data reflecting the current state of our American health care system
• Describe the Triple Aim and how it can guide reform of patient care and health care costs
• Examine the concept of meaningful use electronic medical records and how these can transform medical data into medical information which, in turn, can drive health care and behavior change
• Present data on existing ACO models to illustrate some successes they have already achieved

Click here to learn more about Alere's data management solutions
Presenter:
Thomas I. Koshy, Ph.D.
Senior Director, Scientific Affairs
Alere 
Tom Koshy Photo
   
Finding Pneumo: The Biological Link between Influenza and Pneumonia and the Importance of Diagnostic Testing
Live event: Friday, November 2, 2012  10:00 AM and 4:00 PM EST
PACE
® credit available until May 1, 2013  |  Florida CE Credit available for live event
View RecordingView Slides
The respiratory season brings with it the challenge of identifying the respiratory infection(s) - Is it flu? Is it bacterial pneumonia? Or is it both?

Pneumococcal pneumonia, the number one secondary bacterial complication of flu as seen in the United States and globally during the 2009 pandemic influenza A (H1N1) underscores the importance of co-infection, for flu and pneumococcal vaccinations for persons at risk and for early recognition of bacterial pneumonia in persons with influenza. This webinar will address the biological link between influenza and bacterial pneumonia and the importance of diagnostic testing during every respiratory season - not just during pandemics.

This webinar will:
· Explain the potential mechanisms of how influenza can predispose a person to pneumococcal pneumonia
· Analyze the clinical significance of influenza associated pneumonia
· Describe the importance of diagnostic testing to enable focused treatment
· Review some of the available diagnostic tools for influenza and pneumococcal pneumonia

Due to the anticipated high demand for this webinar, it will be presented live twice on November 2nd.

Finding Pneumo cropped gfxClick here to learn more about Alere's influenza solution
Click here to learn more about Alere’s pneumococcal pneumonia solution.
Presenter:
Keith P. Klugman, MB BCh, PhD, FAAM, FIDSA

Professor of Medicine
Division of Infectious Diseases
Emory University School of Medicine
Keith Klugman pic
   
Spotting and Surviving Sepsis
Live event: Wednesday, September 12, 2012  11:00 AM EDT
PACE
® credit available until March 11, 2013  |  Florida CE Credit available for live event
View RecordingView Slides
Sepsis is defined as systemic overwhelming immune response to infection. The clinical presentation of sepsis can be subtle and difficult to identify, but the consequences can be sudden and catastrophic. Mortality rates for sepsis are higher than those seen for cancer and heart attacks, and the incidence has been rising steadily for the past 10 years.

For these reasons, controlling the morbidity and mortality of sepsis has become a high priority for many hospitals across the country. This webinar will help healthcare professionals identify sepsis before organ and system failure and describe the guideline recommendations for the early treatment of sepsis. It will also identify situations where point of care analyte testing might benefit patients with a suspected or confirmed diagnosis of sepsis.

This webinar will:
Discuss the scope of sepsis morbidity and mortality
Describe the role of sepsis biomarkers in screening, diagnosis, risk stratification, and monitoring of response to therapy in sepsis
Analyze factors to be considered when evaluating sepsis testing and results
Apply information to assist in the identification and treatment of patients with sepsis and improve patient outcomes

Click here to learn more about Alere's Sepsis solutions
Presenter:
Thomas I. Koshy, Ph.D.
Senior
Director, Scientific Affairs
Alere
Tom Koshy Pic
   
Evaluating Multi-step Testing Algorithms in Diagnosing Clostridium difficile Infections 
Live event: Thursday, March 22, 2012  10:00 AM and 4:00 PM EST  
PACE
® credit available until Sept 21, 2014  |  Florida CE Credit available for live event
View RecordingView Slides
C. difficile testing remains challenging due to the changing landscape of C. difficile infection and number of different testing options available. These challenges make it difficult to determine the best methodology for identifying patients with C. difficile disease. Accurate detection of C. difficile-infected patients is the key to providing proper patient care. This highly acclaimed webinar will address changes in C. difficile infection epidemiology and look in depth at different testing options and their impact on laboratory finances and workflow.

This webinar will:

Define the changing epidemiology of C. difficile infection
Outline the evolution of different testing algorithms for C. difficile infection
Compare the cost effectiveness of different testing approaches for C. difficile infection
Explain the theoretical basis for false positive molecular tests for C. difficile 

Click here to learn more about Alere's C. difficile solutions.
Presenter:
Peter H. Gilligan, PhD
Professor, Pathology-Laboratory Medicine and Microbiology-Immunology
UNC School of Medicine 
Dr. P Gilligan
   
The Role of Natriuretic Peptides in the Prognosis and Management of ACS
Live Event: Tuesday, February 28, 2012 11:00 AM Eastern  
PACE® credit available until August 28, 2012  |  Florida CE Credit available for live event
View RecordingView Slides
Treatment options for ACS patients presenting to the Emergency Department are numerous. Risk stratification in Acute Coronary Syndromes with B-type Natriuretic Peptide (BNP) may aid physicians in selecting the most appropriate treatment regimens for improved patient outcomes. Dr McCullough’s presentation will include case studies which illustrate how risk stratification with BNP can improve both patient triage and treatment decisions.

BNP Graphic
This webinar will:

Evaluate the published studies on BNP and myocardial ischemia
Examine the use of a recommended BNP in ACS algorithm
Interpret results of BNP in the setting of ACS to better individualize therapeutic strategies




Click here to learn more about Alere's heart failure diagnostics solutions.
Presenter:
Peter A. McCullough, MD
Chief Academic and Scientific Officer
St. John Providence Health System
Detroit, MIPeter McCullough
   
Clinical Applications of D-dimer Testing at the Point of Care

Live event: Thursday, January 12, 2012  11:00 AM Eastern  |  PACE® credit available until July 11, 2012
View RecordingView Slides
Venous Thromboembolism presents subtly and often kills rapidly. A patient’s life or death can be decided in the diagnostic process. Venous Thromboembolism (VTE), which encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE) is the fourth leading cause of death in the US. It is responsible for 200,000 deaths annually - more than AIDS and breast cancer combined. And most PE deaths occur before the diagnosis is made, making it a leading cause of unexplained death in the ED. D-dimer is the test of choice in diagnosing VTE and PE. Considering the alarming number of PE deaths that occur within the first 60 minutes, the results must be rapid and accurate.

Whether testing is performed in the lab or at the point of care, speed is achieved with minimal preanalytical processing. The knowledge provided in this webinar will improve your understanding of VTE and the significant benefits of D-dimer testing to its diagnosis.

PE GraphicThis webinar will:

Describe the role of risk assessment in the evaluation of Venous Thromboembolic Disease
Clarify the role of D-dimer in the exclusion of Venous Thromboembolic Disease
Discuss the role of point of care testing for D-dimer
Analyze D-dimer’s role in the clinical assessment of disseminated intravascular coagulation


Click here to learn more about Alere's D-dimer solutions.
Presenter:
Kent Lewandrowski, MD
Director of Clinical Laboratories and Molecular Medicine and
Associate Chief of Pathology
Massachusetts General Hospital
Kent Lewandrowski
   
POC Cardiac Marker Testing: Rapid Multi-Marker vs. Troponin-Only Strategies
Live event: Thursday, December 15, 2011 11:00 AM Eastern  |  PACE® credit available until June 14, 2012
View RecordingView Slides
When it comes to myocardial infarction there is consensus that time is muscle and it is imperative to rapidly identify MI patients. While there has been much progress in hospitals nationwide in the rapid diagnosis and treatment of STEMIs, more can and should be done with n-STEMIs. This is evidenced by the re-definition of MI and the CMS mandate for a 60 minute maximum time for ED door to first Troponin result. However, this is where the consensus ends as there is much confusion about exactly how this should be accomplished. In this webinar, Dr. Maloney offers his experience with a practical approach for rapid disposition of patients presenting to the ED with chest pain.

This webinar will:
Analize the implications of CMS changes on ED practice
Appraise Rapid Multi-marker vs. Troponin-only strategies
Examine proven strategies for effective evaluation of chest pain patients

Download Dr. Maloney's Flow charts:
Flow chart - Atypical Chest Pain
Flow chart - Acute STEMI

Click here to learn more about Alere's Cardiac Marker solutions.
Presenter:
William E. Maloney, MD, FACEP
Chair, Department of Emergency Medicine
Advocate Condell Medical Center
Libertyville, IL
Dr. W Maloney
   
The Critical Role of Rapid Diagnosis in Venous Thromboembolism 
Live event: Wednesday, March 16, 2011   |   PACE® credit no longer available
View Recording View Slides
Venous Thromboembolism presents subtly and often kills rapidly. A patient’s life or death can be decided in the diagnostic process. Venous Thromboembolism (VTE), which encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE) is the fourth leading cause of death in the US. It is responsible for 200,000 deaths annually - more than AIDS and breast cancer combined. And most PE deaths occur before the diagnosis is made, making it a leading cause of unexplained death in the ED. D-dimer is the test of choice in diagnosing VTE and PE. Considering the alarming number of PE deaths that occur within the first 60 minutes, the results must be rapid and accurate. Whether testing is performed in the lab or at the point of care, speed is achieved with minimal preanalytical processing. The knowledge provided in this webinar will improve your understanding of VTE and the significant benefits of D-dimer testing to its diagnosis.

This webinar will:

Review the pathophysiology of venous thromboembolism
Illustrate the diagnostic modalities for the diagnosis of PE and DVT
Discuss the proper use of D-dimer assays to aid in the assessment of VTE
Clarify the advantages of performing D-dimer assays at the point of care 

Click here to learn more about Alere's D-dimer solutions.
Presenter:
Howard J. Kirchick, PhD
Director of Scientific Affairs, Alere 
Dr. H Kirchick
   
Measuring Natriuretic Peptides in Acute Coronary Syndromes
Live Event:  Tuesday, December 14, 2010   |   PACE® credit no longer available
View Recording View Slides
This webinar will:
Review the pathophysiologic determinants of BNP secretion
Appraise the published studies on BNP and myocardial ischemia
Interpret results of BNP in the setting of ACS to better individualize therapeutic strategies
Clarify the use of a new BNP in ACS algorithm 

Click here to learn more about Alere's heart failure diagnostics solutions.
Presenter:
Peter A. McCullough, MD
Consultant Cardiologist, Chief Academic and Scientific Officer
St. John Providence Health System
Providence Park Heart Institute
Novi, MI 
Dr. P McCollough
   
More Educational Resources POC Webinars
Alere's commitment to education extends to our sponsorship of all point of care group webinars since 2011, which are produced by Whitehat Communications and free to the point of care and laboratory community. You can register for the 2014 sessions and view the recorded sessions held in 2013 and 2012 as follows:

Click here to register for any of the 2014 Point of Care group webinars

Click here to view the recorded Point of Care group webinars held in 2013
 
© 2014 | Whitehat Communications, a division of Martek Inc.